Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. [electronic resource]
Producer: 20131104Description: 981-8 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease-Free Survival
- Docetaxel
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Quinazolines -- therapeutic use
- Taxoids -- therapeutic use
- ras Proteins -- genetics
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.